P2X7 Receptor Antagonist Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

March 22 04:18 2023
P2X7 Receptor Antagonist Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, P2X7 Receptor Antagonist pipeline constitutes key companies continuously working towards developing P2X7 Receptor Antagonist treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

P2X7 Receptor Antagonist Overview

The purinergic P2X7 receptor (P2X7R) is a transmembrane protein whose expression has been related to a variety of cellular processes, while its dysregulation has been linked to inflammation and cancer. P2X7R is expressed in cancer and immune system cell surfaces. ATP plays a key role in numerous metabolic processes due to its abundance in the tumour microenvironment.P2X7R plays an important role in cancer by interacting with ATP.

 

P2X7 Receptor Antagonist Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the P2X7 Receptor Antagonist Market.

 

The P2X7 Receptor Antagonist Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the P2X7 Receptor Antagonist Pipeline Report:

  • Companies across the globe are diligently working toward developing novel P2X7 Receptor Antagonist treatment therapies with a considerable amount of success over the years. P2X7 Receptor Antagonist Key players such as – Evotec AG, Janssen Pharmaceutical, Phoenicis Therapeutics, RaQualia Pharma, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, and others, are developing therapies for the P2X7 Receptor Antagonist treatment 
  • P2X7 Receptor Antagonist Emerging therapies such as – EVT 401, JNJ-55308942, PTM 001, AK 1780, and others are expected to have a significant impact on the P2X7 Receptor Antagonist market in the coming years.   
  • In June 2022, Janssen Pharmaceutical initiated a trial titled, “A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression”. The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6

 

P2X7 Receptor Antagonist Pipeline Therapeutics Assessment

  • P2X7 Receptor Antagonist Assessment by Product Type
  • P2X7 Receptor Antagonist By Stage and Product Type
  • P2X7 Receptor Antagonist Assessment by Route of Administration
  • P2X7 Receptor Antagonist By Stage and Route of Administration
  • P2X7 Receptor Antagonist Assessment by Molecule Type
  • P2X7 Receptor Antagonist by Stage and Molecule Type

 

DelveInsight’s P2X7 Receptor Antagonist Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging P2X7 Receptor Antagonist Drugs Under Different Phases of Clinical Development Include:

  • Research programme: purinergic: P2X7 receptor antagonists: Integral Molecular
  • EVT 401: Evotec AG
  • JNJ-55308942: Janssen Pharmaceutical
  • PTM 001: Phoenicis Therapeutics
  • AK 1780: RaQualia Pharma

 

Get a Free Sample PDF Report to know more about P2X7 Receptor Antagonist Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/p2x7-receptor-antagonist-pipeline-insight

 

P2X7 Receptor Antagonist Pipeline Analysis:

The P2X7 Receptor Antagonist pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of P2X7 Receptor Antagonist with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for P2X7 Receptor Antagonist Treatment.
  • P2X7 Receptor Antagonist key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • P2X7 Receptor Antagonist Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the P2X7 Receptor Antagonist market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further P2X7 Receptor Antagonist product details are provided in the report. Download the P2X7 Receptor Antagonist pipeline report to learn more about the emerging P2X7 Receptor Antagonist therapies

 

P2X7 Receptor Antagonist Pipeline Market Drivers

  • Increase in research and development activities
  • Potential of P2X7 Receptor antagonist in treatment of various diseases

 

P2X7 Receptor Antagonist Pipeline Market Barriers

  • No P2X7 Receptor Antagonist in the market
  • Lack of specificity of some antagonists and antibodies related to the P2X7 receptor

 

Scope of P2X7 Receptor Antagonist Pipeline Drug Insight    

  • Coverage: Global
  • Key P2X7 Receptor Antagonist Companies: Evotec AG, Janssen Pharmaceutical, Phoenicis Therapeutics, RaQualia Pharma, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, and others
  • Key P2X7 Receptor Antagonist Therapies: EVT 401, JNJ-55308942, PTM 001, AK 1780, and others
  • P2X7 Receptor Antagonist Therapeutic Assessment: P2X7 Receptor Antagonist current marketed and P2X7 Receptor Antagonist emerging therapies
  • P2X7 Receptor Antagonist Market Dynamics: P2X7 Receptor Antagonist market drivers and P2X7 Receptor Antagonist market barriers 

 

Request for Sample PDF Report for P2X7 Receptor Antagonist Pipeline Assessment and clinical trials

 

Table of Contents

1

P2X7 Receptor Antagonist Report Introduction

2

P2X7 Receptor Antagonist Executive Summary

3

P2X7 Receptor Antagonist Overview

4

P2X7 Receptor Antagonist- Analytical Perspective In-depth Commercial Assessment

5

P2X7 Receptor Antagonist Pipeline Therapeutics

6

P2X7 Receptor Antagonist Late Stage Products (Phase II/III)

7

P2X7 Receptor Antagonist Mid Stage Products (Phase II)

8

P2X7 Receptor Antagonist Early Stage Products (Phase I)

9

P2X7 Receptor Antagonist Preclinical Stage Products

10

P2X7 Receptor Antagonist Therapeutics Assessment

11

P2X7 Receptor Antagonist Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

P2X7 Receptor Antagonist Key Companies

14

P2X7 Receptor Antagonist Key Products

15

P2X7 Receptor Antagonist Unmet Needs

16 

P2X7 Receptor Antagonist Market Drivers and Barriers

17

P2X7 Receptor Antagonist Future Perspectives and Conclusion

18

P2X7 Receptor Antagonist Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about P2X7 Receptor Antagonist drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

  Categories: